Literature DB >> 9860389

Calcaneal ultrasound bone densitometry in inflammatory bowel disease--a comparison with double x-ray densitometry of the lumbar spine.

W Fries1, M Dinca, G Luisetto, F Peccolo, F Bottega, A Martin.   

Abstract

OBJECTIVE: The aim of this study was to measure ultrasound (US) densitometric parameters [Broadband Ultrasound Attenuation (BUA), Speed of Sound (SOS), and stiffness of the os calcis] in patients with inflammatory bowel disease (IBD) and to compare the results with those obtained with conventional x-ray absorptiometry (DXA) of the lumbar spine.
METHODS: Twenty-two patients with Crohn's disease (13 with ileal and nine with ileocolonic disease), 11 patients with ulcerative colitis (eight with left-sided and three with pancolitis), and 18 healthy controls. US densitometry of the right heel and DXA of the lumbar spine were performed within the same day.
RESULTS: Compared to controls, IBD patients had significantly lower values with both methods, US and DXA. Forty-nine percent of patients had a lumbar T score below -1. Calcaneal SOS and stiffness of these patients were significantly reduced (p < 0.03 and p < 0.05, respectively). Positive significant correlations were found between lumbar DXA and calcaneal US parameters. Lumbar bone density and calcaneal US stiffness correlated inversely with the lifetime prednisone intake (p < 0.03 andp < 0.05, respectively), but not with age or duration of disease. A cut-off level of 80 dB/MHz for calcaneal BUA predicted axial osteopenia correctly in 74%, but some underestimation of spinal BMD was observed, especially in female patients with Crohn's disease.
CONCLUSION: US evaluation of the os calcis gives results similar to those of conventional DXA and therefore may be used for screening IBD patients for axial osteoporosis. Because US does not expose patients to radiation, repeated measurements are possible and may be used to assess short term variations and the effect of treatment of IBD-associated bone disease.

Entities:  

Mesh:

Year:  1998        PMID: 9860389     DOI: 10.1111/j.1572-0241.1998.00685.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

Review 1.  Bone abnormalities in gastrointestinal and hepatic disease.

Authors:  F A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  Ultrasound of the skeleton: review of its clinical applications and pitfalls.

Authors:  R D Danese; A A Licata
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 3.  Exercise and Crohn's disease: speculations on potential benefits.

Authors:  Victor Ng; Wanda Millard; Constance Lebrun; John Howard
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

4.  Musculoskeletal Ultrasound to Identify Subclinical Joint and Periarticular Involvement in Patients With Inflammatory Bowel Disease: A Systematic Literature Review.

Authors:  Garifallia Sakellariou; Annalisa Schiepatti; Davide Scalvini; Francesca Lusetti; Erica Fazzino; Federico Biagi; Carlomaurizio Montecucco
Journal:  Front Med (Lausanne)       Date:  2022-05-16

5.  Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis.

Authors:  P Szafors; H Che; T Barnetche; J Morel; C Gaujoux-Viala; B Combe; C Lukas
Journal:  Osteoporos Int       Date:  2018-06-16       Impact factor: 4.507

6.  Bone ultrasonography in glucocorticoid-induced osteoporosis.

Authors:  C Cepollaro; S Gonnelli; P Rottoli; A Montagnani; C Caffarelli; D Bruni; N Nikiforakis; A Fossi; S Rossi; R Nuti
Journal:  Osteoporos Int       Date:  2004-10-01       Impact factor: 4.507

7.  Quantitative ultrasound does not identify patients with an inflammatory disease at risk of vertebral deformities.

Authors:  A Caroline Heijckmann; Bianca Dumitrescu; Arie C Nieuwenhuijzen Kruseman; Piet Geusens; Bruce H R Wolffenbuttel; Jolanda De Vries; Marjolein Drent; Maya S P Huijberts
Journal:  BMC Musculoskelet Disord       Date:  2008-05-20       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.